DOT1L inhibition does not modify the sensitivity of cutaneous T cell lymphoma to pan-HDAC inhibitors in vitro

Cutaneous T-cell lymphomas (CTCLs) are a subset of T-cell malignancies presenting in the skin. The treatment options for CTCL, in particular in advanced stages, are limited. One of the emerging therapies for CTCL is treatment with histone deacetylase (HDAC) inhibitors. We recently discovered an evol...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwesi-Maliepaard, Eliza Mari, Malik, Muddassir, van Welsem, Tibor, van Doorn, Remco, Vermeer, Maarten H., Vlaming, Hanneke, Jacobs, Heinz, van Leeuwen, Fred
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Genetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681147/
https://www.ncbi.nlm.nih.gov/pubmed/36425063
http://dx.doi.org/10.3389/fgene.2022.1032958

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681147/
https://www.ncbi.nlm.nih.gov/pubmed/36425063
http://dx.doi.org/10.3389/fgene.2022.1032958

Ejemplares similares